Latest Competition News

MoneyMe Limited reported a robust FY25 with a $1.6 billion loan book, 28% growth from FY24, and a $24 million operating cash profit, signaling a strong turnaround. The fintech lender also improved credit quality and expanded funding capacity, setting the stage for future growth.

X2M Connect reports a 43% revenue decline in FY25 but improves gross margins and expands into the Middle East and renewable energy sectors, setting a positive outlook for FY26.

X2M Connect Limited reported a $12.1 million loss for FY25, driven by a 43% revenue drop amid a softer South Korean market and the strategic exit from China. Despite cost cuts and improved margins, the company’s adjusted EBITDA loss widened, prompting a $5.4 million capital raise to shore up its balance sheet.

MoneyMe Limited posted a statutory net loss of $66.6 million for FY25, driven by accounting adjustments and credit loss provisions despite strong loan book growth and funding advances. The company is poised for growth with a new credit card launch and ongoing AI integration.

Ramsay Health Care has announced a fully franked ordinary dividend of AUD 0.40 per share for the six months ending June 2025, signaling steady returns for shareholders.

Raiz Invest Limited reported a robust FY25 with 15% revenue growth and a 147% jump in underlying EBITDA, driven by innovative products and AI-powered marketing. The company projects further earnings growth in FY26 amid expanding customer base and strategic partnerships.

RPM Automotive Group reported a mixed FY25 with a slight revenue decline but improved profitability and launched a tyre recycling initiative signaling a strategic shift.

Raiz Invest reported robust FY25 results with 15% revenue growth and a near break-even net loss, underpinned by strong customer and funds growth. The fintech’s strategic innovations and partnerships set a positive tone for FY26.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.